{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T06:29:06Z","timestamp":1786688946848,"version":"build-2736575974"},"reference-count":5,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T00:00:00Z","timestamp":1786665600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T00:00:00Z","timestamp":1786665600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"DOI":"10.1007\/s10557-026-07927-x","type":"journal-article","created":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T05:50:26Z","timestamp":1786686626000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cardiotoxicity of Targeted Cancer Therapies: Expanding the Translational Horizon"],"prefix":"10.1007","author":[{"given":"Minmin","family":"Pan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jizhou","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,14]]},"reference":[{"issue":"3","key":"7927_CR1","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1007\/s10557-025-07790-2","volume":"40","author":"A Chhabra","year":"2026","unstructured":"Chhabra A, Sharma V, Singh TG. Cardiotoxicity induced by targeted cancer therapies: understanding the risks and developing solutions. Cardiovasc Drugs Ther. 2026;40(3):1145\u201359. https:\/\/doi.org\/10.1007\/s10557-025-07790-2.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"4","key":"7927_CR2","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1007\/s10557-024-07604-x","volume":"39","author":"CA Gongora","year":"2025","unstructured":"Gongora CA, Zhang L, Mattei JL, et al. Are sodium-glucose cotransporter-2 inhibitors the cherry on top of cardio-oncology care? Cardiovasc Drugs Ther. 2025;39(4):849\u201356. https:\/\/doi.org\/10.1007\/s10557-024-07604-x.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"3","key":"7927_CR3","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1007\/s10557-025-07769-z","volume":"40","author":"J Yan","year":"2026","unstructured":"Yan J, Lin K, Dai S, et al. Class effect of SGLT2 inhibitors against doxorubicin-induced cardiotoxicity via regulating adenosine kinase mediated-cardiac oxidative stress. Cardiovasc Drugs Ther. 2026;40(3):971\u201385. https:\/\/doi.org\/10.1007\/s10557-025-07769-z.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"5","key":"7927_CR4","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1007\/s10741-025-10531-0","volume":"30","author":"S Shil","year":"2025","unstructured":"Shil S, Kumar P, Mumbrekar KD. Cancer therapy-induced cardiotoxicity: mechanisms and mitigations. Heart Fail Rev. 2025;30(5):1075\u201392. https:\/\/doi.org\/10.1007\/s10741-025-10531-0.","journal-title":"Heart Fail Rev"},{"key":"7927_CR5","doi-asserted-by":"publisher","unstructured":"Nechita LC, Tutunaru D, Nechita A, et al. AI and smart devices in cardio-oncology: advancements in cardiotoxicity prediction and cardiovascular monitoring. Diagnostics (Basel). 2025;15(6). https:\/\/doi.org\/10.3390\/diagnostics15060787.","DOI":"10.3390\/diagnostics15060787"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-026-07927-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10557-026-07927-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-026-07927-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T05:50:26Z","timestamp":1786686626000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10557-026-07927-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,14]]},"references-count":5,"alternative-id":["7927"],"URL":"https:\/\/doi.org\/10.1007\/s10557-026-07927-x","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"value":"0920-3206","type":"print"},{"value":"1573-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,14]]},"assertion":[{"value":"15 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","label":"Competing Interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}